Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma

Pu WANG; Cai-Xia LI; Ying ZHANG; Jia CHEN; Xiao-Chen CHEN; Dan YANG; Jin ZHOU; Xiang-Ping ZONG; Zhen YANG; Meng WU; Ming-Zi YANG; Yu-Qin SONG; Jun ZHU; De-Pei WU.
Chinese Journal of Hematology ; (12): 198-203, 2020.
Artículo en Zh | WPRIM | ID: wpr-1012169

Documentos relacionados

  1. [Autologous hematopoietic stem cell transplantation treatment for T cell lymphoblastic lymphoma].
  2. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
  3. CD19 CAR T Cells.
  4. Clinical use of CAR T-cells in treating acute lymphoblastic leukemia.
  5. Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation.
  6. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
  7. Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  8. Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia.
  9. Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
  10. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.